<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151237">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131312</url>
  </required_header>
  <id_info>
    <org_study_id>999908076</org_study_id>
    <secondary_id>08-C-N076</secondary_id>
    <nct_id>NCT01131312</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)</brief_title>
  <official_title>Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Approximately 65 million Pap smears are performed each year in the United States. The vast
      majority of results are negative (no abnormality identified) but about 5 percent to 8
      percent are reported as abnormal. Most low-grade changes regress spontaneously; only a
      minority of such lesions would progress to a cancer precursor without treatment. However,
      there is no way to determine morphologically which patients are at risk or progression.
      Therefore, both high- and low-grade lesions were often managed with colposcopy and directed
      biopsy. It was anticipated that determining alternative management strategies would yield
      important potential benefits including fewer medical complications from over treatment,
      reduced patient anxiety associated with referral for cytologic abnormalities, as well as
      cost savings.

      Epidemiologic, virologic and molecular studies have clearly demonstrated that human
      papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the ALTS
      trial was to use the information we have gained about the role of HPV to design better
      treatment and prevention strategies to reduce the burden of cervical cancer and its
      precursors.

      ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2)
      repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV
      testing and repeat cytology in combination, with referral to colposcopy if either the HPV
      test is positive or the cytology shows a high grade lesion. Four Clinical Centers University
      of Alabama, Birmingham AL; Magee-Womens Hospital, Pittsburgh PA; University of Oklahoma,
      Oklahoma City OK; and University of Washington, Seattle WA enrolled approximately 5,000
      women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month
      intervals for a total of 2 years. The main results from ALTS showed that for women with
      ASCUS cytology, HPV triage was at least as safe as universal immediate colposcopy in the
      detection of high-grade lesion and would allow approximately half of women to return to
      routine follow up without additional procedures (colposcopy). No efficient triage strategy
      was identified for women with LSIL cytology.

      The ALTS database and ALTS specimens continue to be a valuable research resource in studies
      of cervical cancer precursors, screening tests, visual assessment of the cervix and
      investigation of biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 65 million Pap smears are performed each year in the United States. The vast
      majority of results are negative (no abnormality identified) but about 5 percent to 8
      percent are reported as abnormal. Most low-grade changes regress spontaneously; only a
      minority of such lesions would progress to a cancer precursor without treatment. However,
      there is no way to determine morphologically which patients are at risk of progression.
      Therefore, both high- and low-grade lesions were often managed with colposcopy and directed
      biopsy. It was anticipated that determining alternative management strategies would yield
      important potential benefits including fewer medical complications from over treatment,
      reduced patient anxiety associated with referral for cytologic abnormalities, as well as
      cost savings.

      Epidemiologic, virologic and molecular studies have clearly demonstrated that human
      papillomavirus (HPV) is the central cause of cervical cancer. The motivation for the ALTS
      trial was to use the information we have gained about the role of HPV to design better
      treatment and prevention strategies to reduce the burden of cervical cancer and its
      precursors.

      ALTS consisted of three management strategies: (1) immediate colposcopy of all women; (2)
      repeat cytology with colposcopy only if the results show a high grade lesion; and (3) HPV
      testing and repeat cytology in combination, with referral to colposcopy if either the HPV
      test is positive or the cytology shows a high grade lesion. Four Clinical Centers University
      of Alabama, Birmingham AL; Magee-Womens Hospital, Pittsburgh PA; University of Oklahoma,
      Oklahoma City OK; and University of Washington, Seattle WA - enrolled approximately 5,000
      women with recent diagnosis of ASCUS or LSIL. Participants were followed at six month
      intervals for a total of 2 years. The main results from ALTS showed that for women with
      ASCUS cytology, HPV triage was at least as safe as universal immediate colposcopy in the
      detection of high-grade lesion and would allow approximately half of women to return to
      routine follow up without additional procedures (colposcopy). No efficient triage strategy
      was identified for women with LSIL cytology.

      The ALTS database and ALTS specimens continue to be a valuable research resource in studies
      of cervical cancer precursors, screening tests, visual assessment of the cervix and
      investigation of biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 20, 2008</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Cumulative detection of pathology QC histologically confirmed CIN3 (cervical precancer) over the 2 years of the trial.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative detection of clinical center histologically confirmed CIN2 and above (high grade lesion) over the 2 years of the trial.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">5060</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>Cervical Smears</condition>
  <condition>HPV DNA Probes</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

        Diagnosis of ASCUS or LSIL

        18 years or older

        Able to give informed consent with reasonable likelihood of follow-up

        Exclusion Criteria:

        Previous Hysterectomy

        History of excisional or ablative treatment of cervix, such as laser treatment, radiation
        therapy, cauterization (burning), freezing or surgery such as cone biopsy or LEEP.

        Already known to be pregnant

        Already known to be HIV positive (HIV may negatively affect the clinical history of HPV,
        making triage less appropriate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark H Schiffman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984 May;3(5):1151-7.</citation>
    <PMID>6329740</PMID>
  </reference>
  <reference>
    <citation>Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995 Mar;172(3):946-54.</citation>
    <PMID>7892889</PMID>
  </reference>
  <reference>
    <citation>Dyson N, Howley PM, MÃ¼nger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989 Feb 17;243(4893):934-7.</citation>
    <PMID>2537532</PMID>
  </reference>
  <verification_date>August 25, 2016</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>May 25, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervix</keyword>
  <keyword>CIN</keyword>
  <keyword>HPV</keyword>
  <keyword>Triage</keyword>
  <keyword>ASCUS/LSIL</keyword>
  <keyword>Pap Smear</keyword>
  <keyword>HPV Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
